Tradipitant, sold under the brand name Nereus, is a medication used as prevention of vomiting induced by motion (motion sickness). It is a neurokinin 1 receptor antagonist. It works by blocking substance P, a small signaling molecule. VLY-686 was purchased by Vanda Pharmaceuticals from Eli Lilly and Company in 2012.
Tradipitant was approved for medical use in the United States in December 2025.
Medical uses Tradipitant is indicated for the prevention of vomiting induced by motion.
Society and culture Legal status Tradipitant was approved for medical use in the United States in December 2025.
Names Tradipitant is the international nonproprietary name.
Tradipitant is sold under the brand name Nereus.
References
External links